HIF1A Antibody / HIF-1 alpha, 100 ul

HIF1A antibody detects hypoxia inducible factor 1 alpha, encoded by the HIF1A gene. HIF-1 alpha is a transcription factor that regulates cellular responses to low oxygen. Under normoxia, HIF-1 alpha is hydroxylated by prolyl hydroxylases, ubiquitinated by the von Hippel Lindau E3 ligase complex, and degraded. Under hypoxia, degradation is inhibited, allowing HIF-1 alpha to accumulate, dimerize with HIF-1 beta, and activate target genes involved in angiogenesis, glycolysis, and survival.

HIF1A antibody is widely applied in cancer research, cardiovascular biology, and metabolism. In tumors, HIF-1 alpha promotes angiogenesis by inducing VEGF and other pro angiogenic factors, supporting tumor growth and metastasis. In ischemic heart disease and stroke, HIF-1 alpha regulates protective adaptations. In metabolism, HIF-1 alpha shifts energy production toward glycolysis, contributing to the Warburg effect in cancer. By detecting HIF-1 alpha, researchers can investigate how hypoxia drives physiological and pathological processes.

Western blot assays detect HIF-1 alpha stabilization in hypoxic cells. Immunohistochemistry maps nuclear accumulation in hypoxic tumor regions, while immunofluorescence highlights dynamic nuclear translocation. ELISA quantifies HIF-1 alpha levels in experimental and clinical samples. These assays make HIF1A antibody an essential reagent for hypoxia biology.

HIF-1 alpha controls genes involved in angiogenesis, erythropoiesis, glucose metabolism, and apoptosis. Dysregulation contributes to cancer progression, ischemic disease, and inflammatory disorders. Therapeutic strategies aim to inhibit HIF-1 alpha in cancer or enhance its activity in ischemic injury. By applying HIF1A antibody, scientists can monitor pathway activity and evaluate therapeutic interventions.

HIF1A antibody from NSJ Bioreagents provides dependable specificity for detecting hypoxia inducible factor 1 alpha. Its performance across multiple assays ensures accurate evaluation of hypoxia signaling in research and clinical contexts.